{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:04:44Z","timestamp":1792062284840,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jtho.2021.03.012","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T20:08:46Z","timestamp":1617480526000},"page":"1570-1581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage\u2013SCLC: Results From the Phase 3 MERU Study"],"prefix":"10.1016","volume":"16","author":[{"given":"Melissa L.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanete","family":"Zvirbule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Laktionov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslaug","family":"Helland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Colinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Gottfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Yu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Nickner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Vajikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Komarnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.03.012_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1183\/09031936.00105009","article-title":"Treatment\u00a0of extensive-stage small cell lung carcinoma: current status and future prospects","volume":"35","author":"Demedts","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2021.03.012_bib2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JOP.18.00278","article-title":"Treatment options for relapsed small-cell lung cancer: what progress have we made?","volume":"14","author":"Qin","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtho.2021.03.012_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.03.012_bib4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.03.012_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/74307","article-title":"Mutations in the\u00a0human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis","volume":"24","author":"Bulman","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.03.012_bib6","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A\u00a0DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in\u00a0vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2021.03.012_bib7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/hmg\/ddq529","article-title":"Notch inhibition by the ligand DELTA-LIKE 3 defines the\u00a0mechanism of abnormal vertebral segmentation in spondylocostal dysostosis","volume":"20","author":"Chapman","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"suppl","key":"10.1016\/j.jtho.2021.03.012_bib8","doi-asserted-by":"crossref","first-page":"S970","DOI":"10.1016\/j.jtho.2018.08.1825","article-title":"P3. 12-02 dynamics of DLL3 and ASCL1 expression in SCLC over disease course","volume":"13","author":"Farago","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in\u00a0recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib10","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.03.012_bib11","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2014.57.3105","article-title":"Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance)","volume":"33","author":"Ready","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib12","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2001.19.8.2114","article-title":"Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group","volume":"19","author":"Schiller","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2021.03.012_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer\u2014what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2021.03.012_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JTO.0b013e31821529c3","article-title":"Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer","volume":"6","author":"Schneider","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jtho.2018.05.002","article-title":"Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC)","volume":"13","author":"Gadgeel","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib17","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus\u00a0placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl\u00a02","key":"10.1016\/j.jtho.2021.03.012_bib18","doi-asserted-by":"crossref","first-page":"ii77","DOI":"10.1093\/annonc\/mdz094","volume":"30","author":"Owonikoko","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.03.012_bib19","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A\u00a0phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.03.012_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A\u00a0phase 1 trial of\u00a0vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2021.03.012_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A\u00a0phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jtho.2021.03.012_bib22","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-08-1315","article-title":"Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors","volume":"15","author":"Hochhauser","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.03.012_bib23","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","article-title":"Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors","volume":"17","author":"Puzanov","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421020670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421020670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:46:16Z","timestamp":1761561976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421020670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1556086421020670"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.03.012","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage\u2013SCLC: Results From the Phase 3 MERU Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}